JP2024514703A - ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 - Google Patents

ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 Download PDF

Info

Publication number
JP2024514703A
JP2024514703A JP2023564639A JP2023564639A JP2024514703A JP 2024514703 A JP2024514703 A JP 2024514703A JP 2023564639 A JP2023564639 A JP 2023564639A JP 2023564639 A JP2023564639 A JP 2023564639A JP 2024514703 A JP2024514703 A JP 2024514703A
Authority
JP
Japan
Prior art keywords
compound
alkyl
cycloalkyl
fluoroalkyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514703A5 (cg-RX-API-DMAC7.html
Inventor
シエ,ユリ
リュ,ヨンツォン
チエン,リフゥイ
ファン,ホウシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of JP2024514703A publication Critical patent/JP2024514703A/ja
Publication of JP2024514703A5 publication Critical patent/JP2024514703A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023564639A 2021-04-22 2022-04-19 ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 Pending JP2024514703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110439238 2021-04-22
CN202110439238.4 2021-04-22
PCT/CN2022/087652 WO2022222921A1 (zh) 2021-04-22 2022-04-19 含哌嗪结构的parp抑制剂、其制备方法及医药用途

Publications (2)

Publication Number Publication Date
JP2024514703A true JP2024514703A (ja) 2024-04-02
JP2024514703A5 JP2024514703A5 (cg-RX-API-DMAC7.html) 2025-04-28

Family

ID=83721971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564639A Pending JP2024514703A (ja) 2021-04-22 2022-04-19 ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用

Country Status (10)

Country Link
US (1) US20240336624A1 (cg-RX-API-DMAC7.html)
EP (1) EP4328224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514703A (cg-RX-API-DMAC7.html)
KR (1) KR20230175225A (cg-RX-API-DMAC7.html)
CN (1) CN117279916B (cg-RX-API-DMAC7.html)
AU (1) AU2022261011A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213029A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012361A (cg-RX-API-DMAC7.html)
WO (1) WO2022222921A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CN116867783B (zh) * 2021-04-23 2026-08-07 康百达(四川)生物医药科技有限公司 吡啶衍生物及其在医药上的应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051812A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
AU2023275808A1 (en) * 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
US20250346573A1 (en) * 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
CN117946074A (zh) * 2022-10-20 2024-04-30 上海海和药物研究开发股份有限公司 具有parp1抑制活性的化合物及其用途
CN120092010A (zh) * 2022-11-02 2025-06-03 轩竹生物科技股份有限公司 多环类聚(adp核糖)聚合酶选择性抑制剂
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
WO2024213111A1 (zh) * 2023-04-14 2024-10-17 微境生物医药科技(上海)有限公司 Parp抑制剂、其制备方法及医药用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500758A (ja) * 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキノリノン誘導体
JP2012515786A (ja) * 2009-01-23 2012-07-12 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
JP2012522007A (ja) * 2009-03-27 2012-09-20 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
JP2018521033A (ja) * 2015-06-09 2018-08-02 ジェ イル ファーマシューティカル カンパニー リミテッド 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物
JP2020512298A (ja) * 2016-12-30 2020-04-23 ミトブリッジ,インコーポレーテッド ポリ−adpリボースポリメラーゼ(parp)阻害剤
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CN117177972A (zh) * 2021-04-19 2023-12-05 新特拉有限公司 Parp1抑制剂及其用途
CN116710433B (zh) * 2021-04-23 2026-05-05 康百达(四川)生物医药科技有限公司 一种选择性parp1抑制剂及其应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500758A (ja) * 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキノリノン誘導体
JP2012515786A (ja) * 2009-01-23 2012-07-12 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
JP2012522007A (ja) * 2009-03-27 2012-09-20 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
JP2018521033A (ja) * 2015-06-09 2018-08-02 ジェ イル ファーマシューティカル カンパニー リミテッド 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物
JP2020512298A (ja) * 2016-12-30 2020-04-23 ミトブリッジ,インコーポレーテッド ポリ−adpリボースポリメラーゼ(parp)阻害剤
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEFFREY W. JOHANNES ET AL.: "Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylp", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 19, JPN6025040755, 27 September 2021 (2021-09-27), pages 14498 - 14512, ISSN: 0005856138 *

Also Published As

Publication number Publication date
US20240336624A1 (en) 2024-10-10
EP4328224A4 (en) 2025-06-18
EP4328224A1 (en) 2024-02-28
CN117279916A (zh) 2023-12-22
CN117279916B (zh) 2026-04-21
MX2023012361A (es) 2023-10-31
AU2022261011A1 (en) 2023-11-16
BR112023021383A2 (pt) 2023-12-19
KR20230175225A (ko) 2023-12-29
WO2022222921A1 (zh) 2022-10-27
CA3213029A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
CN117279916B (zh) 含哌嗪结构的parp抑制剂、其制备方法及医药用途
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
JP7850663B2 (ja) スピロ環含有キナゾリン化合物
JP7773987B2 (ja) スピロ環含有キナゾリン化合物
CN114901661B (zh) 新型K-Ras G12C抑制剂
CN118434725B (zh) 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
KR100281867B1 (ko) 3-(비스-치환페닐메틸렌)옥신돌유도체
CN115974855B (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
JP2004250329A (ja) イサチン誘導体
CN111606890A (zh) 含丙烯酰基的核转运调节剂及其用途
CN113880804A (zh) 新型苯并咪唑化合物
JP2024105489A (ja) Μgaτ2阻害活性を有する縮合環誘導体の製造方法
RU2857202C2 (ru) Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
TWI845843B (zh) 新型吡嗪化合物
JP2024524933A (ja) Idh変異体阻害剤およびその使用
CN115768775B (zh) Idh突变体抑制剂及其用途
CN118108704A (zh) Kif18a抑制剂
RU2860311C2 (ru) Ингибитор мутанта idh и его применение
WO2024213111A1 (zh) Parp抑制剂、其制备方法及医药用途
CN121517424A (zh) PI3Kα抑制剂及其制备方法和医药用途
JP2025540298A (ja) Hdac阻害剤およびその使用
WO2022228511A1 (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260512